TULSA-PRO® Was Front and Center at AUA2022

Activities Highlighting Profound’s Ground-Breaking Technology Included a Semi-Live TULSA Procedure Performed by UT Southwestern’s Dr. Kenneth A. Goldberg During Meeting’s Plenary Session Activities Highlighting Profound’s Ground-Breaking Technology Included a Semi-Live TULSA Procedure Performed by UT Southwestern’s Dr. Kenneth A. Goldberg During Meeting’s Plenary Session

Profound Medical Clarifies Recent Insider Buying

TORONTO, May 18, 2022 (GLOBE NEWSWIRE) — In response to investor inquiries regarding insider trading activity, particularly with respect to recent open market stock purchases made by certain of its insiders, Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today provided the following clarifications.

Profound Medical to Participate in June Investor Conferences

TORONTO, May 25, 2021 (GLOBE NEWSWIRE) — Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in two investor conferences in June.

Profound Medical to Release Second Quarter 2021 Financial Results on August 4 – Conference Call to Follow

TORONTO, July 15, 2021 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2021 financial results after market close on Wednesday, August 4, 2021.

Profound Medical to Participate in A.G.P.’s Virtual MedTech Summer Conference

TORONTO, July 22, 2021 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in A.G.P.’s Virtual MedTech Summer Conference on Thursday, July 29, 2021.

Profound Medical Announces Second Quarter 2021 Financial Results

TORONTO, Aug. 04, 2021 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the second quarter ended June 30, 2021.

Profound Medical to Participate in September Virtual Investor Conferences

TORONTO, Sept. 08, 2021 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announce today that management will participate in two investor conferences in September.

Profound Medical to Release Third Quarter 2021 Financial Results on November 4 – Conference Call to Follow

TORONTO, Oct. 18, 2021 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2021 financial results after market close on Thursday, November 4, 2021.

Profound Medical to Participate in November Virtual Investor Conferences

TORONTO, Nov. 01, 2021 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in two investor conferences in November.

Profound Medical Announces Third Quarter 2021 Financial Results

TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended September 30, 2021.